Mode
Text Size
Log in / Sign up
N/A N=238 Randomized Double-blind Basic Science

Very-Low Nicotine Cigarettes and Non-Daily Smokers

Smoking

Enrolled (actual)
238
Serious AEs
1.3%
Results posted
Oct 2018
Primary outcome: Primary: Change in Cigarette Consumption — -1.6; -0.05 cigarettes per day — p=<0.001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Very low nicotine content cigarettes (Drug); Normal nicotine content cigarettes (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Saul Shiffman
Primary completion
Jul 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Cigarette Consumption
-1.6; -0.05 <0.001 sig
SECONDARY
Exposure Measure - Solanesol
NA; NA
SECONDARY
Exposure Measure - Smoking Topography
501.20; 539.70 0.041 sig
SECONDARY
Exposure Measure - Cotinine (Logged)
-0.84; -0.15 0.016 sig
SECONDARY
Exposure Measure - Cigarette Butt Weight
0.58; 0.60 0.03 sig

Summary

The purpose of this research study is to investigate the impact of different nicotine levels in cigarettes among non-daily smokers. This research may help inform the Food and Drug Administration (FDA) on how best to regulate tobacco products in the future, with the goal of improving public health.

Eligibility Criteria

Inclusion Criteria

  • age 18 years or older, and smoking cigarettes for at least 3 years
  • smoking, on average, 4-27 days per month
  • smoking at current rate for at least the previous 3 months
  • willingness to try novel cigarettes

Exclusion Criteria

  • active plans to quit or actively seeking smoking cessation treatment in the next 3 months
  • severe psychiatric disorders that may interfere with study procedures
  • current, regular (i.e., monthly or more) use of nicotine replacement or other tobacco products, by self-report
  • exclusive use of roll-your-own cigarettes (since the study uses manufactured cigarettes)
  • [for female participants] being pregnant or breastfeeding, or planning to become pregnant, by self-report
  • current use of medications such as Chantix (varenicline), Zyban, Wellbutrin, or bupropion for any purpose, including stopping smoking
  • occurrence of heart attack, stroke, or angina in the past 3 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02228824). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search